JP7662204B2 - エンドキシフェンの徐放性組成物 - Google Patents

エンドキシフェンの徐放性組成物 Download PDF

Info

Publication number
JP7662204B2
JP7662204B2 JP2022500075A JP2022500075A JP7662204B2 JP 7662204 B2 JP7662204 B2 JP 7662204B2 JP 2022500075 A JP2022500075 A JP 2022500075A JP 2022500075 A JP2022500075 A JP 2022500075A JP 7662204 B2 JP7662204 B2 JP 7662204B2
Authority
JP
Japan
Prior art keywords
sustained release
hours
endoxifen
release composition
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022500075A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538911A (ja
JP2022538911A5 (cg-RX-API-DMAC7.html
Inventor
スティーブン シー． キー，
ナレシュ クマール レディ ビュートゥクル，
スリニバサン シャンムガム，
Original Assignee
アトッサ・セラピューティクス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アトッサ・セラピューティクス・インコーポレイテッド filed Critical アトッサ・セラピューティクス・インコーポレイテッド
Publication of JP2022538911A publication Critical patent/JP2022538911A/ja
Publication of JP2022538911A5 publication Critical patent/JP2022538911A5/ja
Application granted granted Critical
Publication of JP7662204B2 publication Critical patent/JP7662204B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022500075A 2019-07-03 2020-07-02 エンドキシフェンの徐放性組成物 Active JP7662204B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962870656P 2019-07-03 2019-07-03
US62/870,656 2019-07-03
US202062989342P 2020-03-13 2020-03-13
US62/989,342 2020-03-13
US202063021549P 2020-05-07 2020-05-07
US63/021,549 2020-05-07
PCT/US2020/040757 WO2021003433A1 (en) 2019-07-03 2020-07-02 Sustained release compositions of endoxifen

Publications (3)

Publication Number Publication Date
JP2022538911A JP2022538911A (ja) 2022-09-06
JP2022538911A5 JP2022538911A5 (cg-RX-API-DMAC7.html) 2023-07-11
JP7662204B2 true JP7662204B2 (ja) 2025-04-15

Family

ID=74100751

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022500075A Active JP7662204B2 (ja) 2019-07-03 2020-07-02 エンドキシフェンの徐放性組成物

Country Status (10)

Country Link
US (2) US12201591B2 (cg-RX-API-DMAC7.html)
EP (1) EP3993782A4 (cg-RX-API-DMAC7.html)
JP (1) JP7662204B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220042352A (cg-RX-API-DMAC7.html)
CN (1) CN114302717A (cg-RX-API-DMAC7.html)
AU (2) AU2020300624B2 (cg-RX-API-DMAC7.html)
CA (1) CA3145867A1 (cg-RX-API-DMAC7.html)
IL (1) IL289557A (cg-RX-API-DMAC7.html)
MX (1) MX2022000203A (cg-RX-API-DMAC7.html)
WO (1) WO2021003433A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021003433A1 (en) * 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
CA3185993A1 (en) * 2020-04-10 2021-10-14 Jina Pharmaceuticals, Inc. Endoxifen for the treatment of bipolar i disorder
AU2022232924A1 (en) * 2021-03-11 2023-07-06 Atossa Therapeutics, Inc. Endoxifen for treatment of ovarian cancer
JP2024541900A (ja) * 2021-10-28 2024-11-13 アトッサ・セラピューティクス・インコーポレイテッド がんの治療のためのエンドキシフェン
EP4514327A1 (en) * 2022-04-26 2025-03-05 Atossa Therapeutics, Inc. High dose endoxifen formulations and methods of use
KR20260020183A (ko) 2023-06-05 2026-02-10 나노파마슈틱스, 인크. 서방성 결정질 prx-3140의 경구 전달을 위한 조성물 및 방법
AU2024409147A1 (en) * 2023-12-18 2026-06-25 Atossa Therapeutics, Inc. Oral formulations of (z)-endoxifen and methods of use thereof
WO2026128516A1 (en) * 2024-12-10 2026-06-18 Atossa Therapeutics, Inc. (z)-endoxifen for neoadjuvant treatment of er+/her2- breast cancer in premenopausal women

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511591A (ja) 2001-11-07 2005-04-28 シントン・ベスローテン・フェンノートシャップ 放出調節型タムスロシン錠
WO2019051416A1 (en) 2017-09-11 2019-03-14 Atossa Genetics Inc. METHODS FOR THE MANUFACTURE AND USE OF ENDOXIFEN

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT951631B (it) 1971-03-18 1973-07-10 Richardson Merrell Spa Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi
GB8604528D0 (en) 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
US6881548B2 (en) 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
US6638727B1 (en) 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
US6398765B1 (en) 1999-03-01 2002-06-04 Pro Duct Health, Inc. Apparatus, methods and kits for simultaneous delivery of a substance to multiple breast milk ducts
US6245352B1 (en) 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Therapy
EP1572178B1 (en) 2002-12-18 2006-05-03 Laboratoires Besins International Treatment of mastalgia with 4-hydroxy tamoxifen
EP2050443B1 (en) 2002-12-18 2017-05-24 Besins Healthcare Luxembourg SARL Reduction of breast density with 4-hydroxy tamoxifen
CA2519980C (en) 2003-04-01 2012-04-10 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
NZ544851A (en) 2003-06-23 2008-03-28 Macrochem Corp A vanishing cream base composition suitable for topical administration of an active agent to an animal or plant
US7531578B2 (en) 2003-09-18 2009-05-12 City Of Hope Compounds and methods for treating breast cancer and other diseases
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
ATE548375T1 (de) 2004-01-16 2012-03-15 Cedarburg Pharmaceuticals Inc Exemestan und zwischenprodukte davon und verfahren zu dessen herstellung
US8436029B2 (en) 2004-03-19 2013-05-07 Transform Pharmaceuticals, Inc. Pharmaceutical forms, and methods of making and using the same
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
CA2603857A1 (en) 2005-03-31 2006-11-16 Mytogen, Inc. Treatment for heart disease
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
KR100917698B1 (ko) 2005-07-06 2009-09-21 시코르, 인크. 레트로졸의 제조를 위한 개선된 방법
CA2617934A1 (en) 2005-08-05 2007-02-15 Nuvo Research Inc. Transdermal drug delivery formulation
US8034824B2 (en) 2005-10-12 2011-10-11 Kowa Co., Ltd. Iontophoretic preparation for treatment of breast cancer and/or mastitis
WO2007067773A2 (en) 2005-12-09 2007-06-14 Mayo Foundation For Medical Education And Research Assessing outcomes for breast cancer patients by determining cyp2d6 genotype
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
US9308181B2 (en) 2006-03-06 2016-04-12 Nuvo Research Inc. Topical formulations, systems and methods
US8058302B2 (en) 2006-06-05 2011-11-15 Cadila Healthcare Limited Process for preparing pure anastrozole
US20100098735A1 (en) 2006-10-05 2010-04-22 Rajesh Jain Injectable depot compositions and its process of preparation
PT2101731T (pt) 2006-11-21 2018-04-18 Jina Pharmaceuticals Inc Endoxifeno para utilização no tratamento de cancro
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
US20120164075A1 (en) * 2006-11-21 2012-06-28 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of mammalian diseases
WO2008066783A2 (en) * 2006-11-27 2008-06-05 Ariad Pharmaceuticals, Inc. Therapeutic materials and methods
WO2008067991A2 (en) 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
WO2008113177A1 (en) 2007-03-20 2008-09-25 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
US8454945B2 (en) 2007-03-22 2013-06-04 Berg Pharma Llc Topical formulations having enhanced bioavailability
US20090068190A1 (en) 2007-08-29 2009-03-12 Drugtech Corporation Anti-proliferative combinations
AR068409A1 (es) 2007-09-14 2009-11-18 Drugtech Corp Composiciones farmaceuticas, transdermicas sin alcohol
EP2212301B1 (en) 2007-11-28 2012-02-29 Fresenius Kabi Oncology Limited An improved process for preparation of letrozole and its intermediates
WO2009120999A2 (en) 2008-03-28 2009-10-01 Olema Pharmaceuticals, Inc. Use of an endoxifen prodrug for treatment of breast cancer
WO2009129352A2 (en) 2008-04-15 2009-10-22 Windy Hill Medical Device and method for accessing and treating ducts of mammary glands
US8063249B1 (en) 2008-04-25 2011-11-22 Olema Pharmaceuticals, Inc. Substituted triphenyl butenes
CA3012229C (en) 2008-07-08 2020-11-10 Incyte Holdings Corporation 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
WO2010009335A1 (en) 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
WO2010043404A1 (en) 2008-10-15 2010-04-22 Synthon B.V. Processes and intermediates for the production of fulvestrant
US20100098659A1 (en) 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
ES2624557T3 (es) 2008-12-11 2017-07-14 Besins Healthcare Luxembourg Sarl Composiciones farmacéuticas transdérmicas que comprenden un SERM
CN101891635B (zh) 2009-05-21 2014-06-04 扬子江药业集团有限公司 枸橼酸他莫昔芬的晶型及晶型a的制备方法
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
CN102470105B (zh) 2009-07-14 2015-07-29 波利皮得有限公司 持续释放药物载体组合物
WO2011031561A2 (en) 2009-08-27 2011-03-17 Ensisheim Partners Llc Nucleic acid molecules and uses thereof
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
WO2011072244A1 (en) 2009-12-10 2011-06-16 Mount Sinai School Of Medicine Of New York University Method of treatment of breast cancer with tamoxifen
EP2425833A1 (de) 2010-09-03 2012-03-07 Fresenius Kabi Deutschland GmbH Die intravenöse Applikation von Fischöl/DHA +EPA vor bzw. mit Beginn der Chemotherapie
KR101308258B1 (ko) 2010-10-15 2013-09-13 씨제이제일제당 (주) 엔독시펜의 신규한 제조 방법
EP2468264A1 (en) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US9200045B2 (en) 2011-03-11 2015-12-01 President And Fellows Of Harvard College Small molecule-dependent inteins and uses thereof
EP2508174A1 (en) * 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
WO2012162492A1 (en) * 2011-05-24 2012-11-29 Teva Pharmaceutical Industries Ltd. Compressed core comprising organic acids for a pharmaceutical composition
WO2013033430A1 (en) 2011-09-02 2013-03-07 Wake Forest School Of Medicine Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
FR2980972B1 (fr) 2011-10-05 2014-02-28 Commissariat Energie Atomique Formulations pour le diagnostic et le traitement de cancers hormonodependants et de cancers des organes de synthese d'hormones steroidiennes.
WO2013134230A1 (en) 2012-03-05 2013-09-12 Xavier University Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer
US9220680B2 (en) 2012-07-13 2015-12-29 South Dakota State University Compositions and methods for localized drug delivery through mammary papillae
US20150321983A1 (en) 2012-10-19 2015-11-12 Fermion Oy A process for the preparation of ospemifene
EP2922847A1 (en) 2012-11-20 2015-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
IL298125A (en) 2013-02-26 2023-01-01 Memorial Sloan Kettering Cancer Center Preparations and methods for immunotherapy
WO2014141292A2 (en) 2013-03-04 2014-09-18 Intas Pharmaceuticals Limited Endoxifen citrate polymorph and process for preparing the same
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
TW201536278A (zh) 2013-05-31 2015-10-01 Del Mar Pharmaceuticals 雙脫水半乳糖醇及其類似物與衍生物用於治療復發性惡性神經膠瘤或進行性繼發腦瘤之用途
EP3057985A4 (en) 2013-10-18 2017-05-31 The Regents Of The University Of Michigan Systems and methods for determining a treatment course of action
HUP1300646A2 (en) 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
EP3092027A4 (en) 2014-01-10 2017-09-06 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
CA2942301A1 (en) 2014-03-11 2015-09-17 Repros Therapeutics Inc. Clomiphene synthesis using a single solvent
EP3152579A4 (en) 2014-06-04 2018-01-17 Atossa Genetics Inc. Molecular mammography
CN104230723B (zh) 2014-08-21 2016-08-24 凯莱英医药集团（天津）股份有限公司 托瑞米芬的合成方法
EP3283061A4 (en) 2015-04-14 2019-04-17 Atossa Genetics Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF BREAST DISEASES AND ORGANISM-RELATED ILLNESSES
WO2016187122A1 (en) 2015-05-15 2016-11-24 University Of Iowa Research Foundation Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy
CA2992282A1 (en) 2015-07-14 2017-01-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders
ES2883172T3 (es) 2015-10-22 2021-12-07 Us Health Proceso para preparar (Z)-endoxifeno de alta pureza
DE102015222031A1 (de) 2015-11-10 2017-05-11 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Synthese von (Z)-Endoxifenhydrochlorid
US20170304232A1 (en) 2016-04-20 2017-10-26 Northwestern University Endoxifen For Local Transdermal Therapy To The Breast
CN111212635A (zh) 2017-09-11 2020-05-29 阿托莎医疗公司 局部用组合物
TW201919594A (zh) 2017-09-11 2019-06-01 美商艾陶莎基因有限公司 局部用組合物及治療方法
WO2021003433A1 (en) * 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511591A (ja) 2001-11-07 2005-04-28 シントン・ベスローテン・フェンノートシャップ 放出調節型タムスロシン錠
WO2019051416A1 (en) 2017-09-11 2019-03-14 Atossa Genetics Inc. METHODS FOR THE MANUFACTURE AND USE OF ENDOXIFEN

Also Published As

Publication number Publication date
EP3993782A4 (en) 2023-08-02
MX2022000203A (es) 2022-03-22
US20250255838A1 (en) 2025-08-14
EP3993782A1 (en) 2022-05-11
CA3145867A1 (en) 2021-01-07
AU2026200417A1 (en) 2026-02-12
IL289557A (en) 2022-03-01
KR20220042352A (ko) 2022-04-05
CN114302717A (zh) 2022-04-08
AU2020300624B2 (en) 2026-02-12
JP2022538911A (ja) 2022-09-06
WO2021003433A1 (en) 2021-01-07
US12201591B2 (en) 2025-01-21
US20220175702A1 (en) 2022-06-09
AU2020300624A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
AU2020300624B2 (en) Sustained release compositions of endoxifen
US12281056B2 (en) Methods for making and using endoxifen
KR20240096623A (ko) 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
US20250281414A1 (en) High dose endoxifen formulations and methods of use
HK40070480A (en) Sustained release compositions of endoxifen
CN108066347B (zh) 包含坦索罗辛和度他雄胺的口腔崩解片药物组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230703

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230703

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240516

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241016

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250327

R150 Certificate of patent or registration of utility model

Ref document number: 7662204

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150